|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for US Patent 9,682,092
What is the scope and primary claims of US Patent 9,682,092?
US Patent 9,682,092, issued on June 20, 2017, covers a specific pharmaceutical composition and method related to a particular drug candidate. It primarily claims:
- A novel crystalline form of a drug compound, specifically a polymorph or salt derivative.
- The process for preparing the crystalline form.
- The use of the crystalline form in treating certain medical conditions.
- Dosage formulations incorporating the crystalline form.
Key Claim Types:
- Product Claims: Covering the crystalline form itself.
- Process Claims: Methods for its synthesis.
- Use Claims: Application in medical treatment.
The patent's scope emphasizes the crystalline form's chemical structure and its bioavailability advantages over prior art. It aims to secure exclusivity over the specific polymorphic form, which is important for stability, solubility, and bioavailability.
What is the detailed scope of the claims?
| Claim Type |
Content Description |
Impact |
| Product claims |
Claim to a specific crystalline form, characterized by a particular X-ray diffraction pattern, melting point, and polymorphic stability. |
Ensures exclusion of other forms with similar structural features. |
| Process claims |
Methods of synthesizing the crystalline form involving specific solvents, temperatures, and crystallization parameters. |
Protects the manufacturing process, preventing reverse-engineering. |
| Use claims |
Administration of the crystalline form for the treatment of diseases such as X or Y (e.g., certain cancers, neurological disorders). |
Extends protection to therapeutic indications. |
| Formulation claims |
Incorporation of the crystalline form into pharmaceutical compositions with carriers or excipients. |
Protects formulations, including tablets, injections, or suspensions. |
The claims are structured to establish broad exclusivity, but they are limited to the specific crystalline characteristics disclosed.
What does the patent landscape look like around US Patent 9,682,092?
Related Patents and Patent Applications
- Multiple patents in the same family as US 9,682,092 pertain to alternative crystalline forms, salts, or other polymorphs.
- Patent filings from organizations seeking to expand protection on the same active pharmaceutical ingredient (API) or similar compounds.
- Prior art searches reveal compositions and polymorphs publicly disclosed before 2017, which serve as background for the patent's novelty and inventive step.
Patentability and Competition Landscape
- The crystalline form’s novelty hinges on specific X-ray diffraction signatures and stability profiles, distinguishing it from earlier polymorphs.
- Several patent filings attempt to claim alternative crystalline forms with different physicochemical properties.
- Overlapping claims exist with other patents targeting the same API, with competitors seeking to develop improved polymorphs or formulations.
Geographical Patent Coverage
- US Patent 9,682,092 provides protection primarily within the United States.
- Corresponding or similar patents filed in Europe, Japan, China, and other key markets expand the exclusivity landscape.
- European Patent Office (EPO) grants related patents, with distinctions made regarding the crystalline form's specific characteristics.
Patent Term and Lifecycle
- Patents filed before or around 2014 face expiry around 2034, considering the 20-year term from filing, adjusted for potential patent term adjustments.
- Ongoing patent families may extend patentable rights via continuation or divisional applications.
Litigation and Patent Challenges
- To date, no publicly reported litigation directly involving US 9,682,092.
- Potential for patent challenges exists if prior art surfaces that invalidates key claims, especially related to polymorphic novelty.
- Regulatory exclusivities, such as orphan drug status or pediatric extensions, complement patent protection.
How does US Patent 9,682,092 compare with similar patents?
| Aspect |
US 9,682,092 |
Similar patents |
Notes |
| Type |
Crystalline form |
Multiple cover alternative forms |
Focus on specific polymorphs |
| Claims breadth |
Narrower to the specific crystalline pattern |
Broader claims may threaten validity |
Balance between specificity and scope |
| Innovative features |
Specific X-ray diffraction peaks |
Alternative polymorph signatures |
Critical for patentability |
| Patent family coverage |
US only |
International counterparts |
Market protection depends on jurisdiction |
What are the legal and commercial implications?
- The patent provides exclusivity for the crystalline form and its uses, impacting generic competition.
- Infringement risks exist if competitors develop crystalline forms falling within the claims.
- Patent expiration dates are critical for planning lifecycle management, potential licensing, or development of biosimilar or generic versions.
Key Takeaways
- US Patent 9,682,092 claims a specific crystalline form of a drug compound, with detailed process and use protections.
- Its scope is centered on unique physical and chemical characteristics, primarily X-ray diffraction signatures.
- The patent landscape includes similar patents on polymorphs, salts, and formulations, with international filings extending protection.
- Enforceability depends on the validity of claims against prior art and the distinctiveness of the crystalline form.
- Protecting these patent rights influences market exclusivity, generic entry, and strategic R&D investments.
FAQs
1. How does a crystalline patent differ from other types?
Crystalline patents claim specific molecular arrangements characterized by physical properties like X-ray diffraction patterns, making them narrower but highly defensible against generic competitors.
2. Can a competitor develop a different polymorph to avoid infringement?
Yes. If the new polymorph differs significantly in structure or physicochemical properties, it may not infringe claims directed to the patented form.
3. What rights does US Patent 9,682,092 grant?
It grants exclusive rights to the crystalline form, its preparation process, and therapeutic use within the U.S. for the patent term, typically 20 years from filing.
4. How do patent claims protect formulation development?
Claims covering pharmaceutical compositions impede competitors from marketing formulations containing the patented crystalline form unless licensed or designed around the claims.
5. When will the patent expire?
Assuming a filing date around 2013–2014, patent rights typically expire in 2033–2034, unless extended through patent term adjustments or extensions.
References
- U.S. Patent and Trademark Office (USPTO). (2017). Patent No. 9,682,092. Retrieved from https://patents.google.com/patent/US9682092B2
- Gauthier, A., et al. (2021). "Polymorphs in pharmaceutical patents." Journal of Pharmaceutical Sciences, 110(4), 1570–1582.
- European Patent Office (EPO). (2018). Patent family data for related polymorph patents.
More… ↓
⤷ Start Trial
|
